Meth-related deaths surge in Oregon | kgw.com
Experts warn meth is cheap, pure and lethal. In 2009, 50 people died in meth-related incidents; in 2018 that number was 272. Source: Meth-related deaths surge in Oregon |...
read moreMeth Plus Opioids: New Hazards Of Dual Addiction : Shots – Health News : NPR
Meth In The Morning, Heroin At Night: Inside The Seesaw Struggle of Dual Addiction Source: Meth Plus Opioids: New Hazards Of Dual Addiction : Shots - Health News :...
read moreDrugFacts: Comorbidity: Substance Use Disorders and Other Mental Illnesses | National Institute on Drug Abuse (NIDA)
...about half of people who experience a mental illness will also experience a substance use disorder at some point in their lives and vice versa. Source: DrugFacts: Comorbidity: Substance Use Disorders and Other Mental Illnesses | National Institute on Drug Abuse...
read moreBinding Methamphetamine to Release People from Addiction
InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of addiction disorders. Our lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS. IXT-m200 has received US FDA Fast Track Designation, and is being studied in an ongoing Phase 2 proof-of-concept study (STAMPOUT; NCT03336866). We are also developing a novel vaccine (IXT-v100) against methamphetamine, which is in Preclinical Development.
Meth-related deaths surge in Oregon | kgw.com
Experts warn meth is cheap, pure and lethal. In 2009, 50 people died in meth-related incidents; in 2018 that number was 272. Source: Meth-related deaths surge in Oregon |...
read moreMeth Plus Opioids: New Hazards Of Dual Addiction : Shots – Health News : NPR
Meth In The Morning, Heroin At Night: Inside The Seesaw Struggle of Dual Addiction Source: Meth Plus Opioids: New Hazards Of Dual Addiction : Shots - Health News :...
read moreDrugFacts: Comorbidity: Substance Use Disorders and Other Mental Illnesses | National Institute on Drug Abuse (NIDA)
...about half of people who experience a mental illness will also experience a substance use disorder at some point in their lives and vice versa. Source: DrugFacts: Comorbidity: Substance Use Disorders and Other Mental Illnesses | National Institute on Drug Abuse...
read moreDeveloping Novel Therapeutics for Addiction
InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of addiction disorders. Our lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS. IXT-m200 is being studied in an upcoming Phase 2 proof-of-concept study (STAMPOUT). We are also developing a novel vaccine (IXT-v100) against methamphetamine.